mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review
A Boretti - Clinical and Experimental Medicine, 2024 - Springer
Over the last 24 months, there has been growing evidence of a correlation between mRNA
COVID-19 vaccine boosters and increased prevalence of COVID-19 infection and other …
COVID-19 vaccine boosters and increased prevalence of COVID-19 infection and other …
Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions
RR Razonable - Expert Opinion on Biological Therapy, 2023 - Taylor & Francis
Introduction Anti-spike monoclonal antibodies were highly effective for prophylaxis and early
treatment of mild-to-moderate COVID-19 in high-risk populations. Areas covered This article …
treatment of mild-to-moderate COVID-19 in high-risk populations. Areas covered This article …
Monoclonal antibody and oral antiviral treatment of SARS-CoV-2 infection in US nursing homes
Methods| The primary data source was the Centers for Disease Control and Prevention
National Healthcare Safety Network (NHSN) Nursing Home COVID-19 database, which …
National Healthcare Safety Network (NHSN) Nursing Home COVID-19 database, which …
Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial
B Maranda, SM Labbé, M Lurquin… - The Lancet Infectious …, 2024 - thelancet.com
Background COVID-19 severity is associated with its respiratory manifestations. Neutralising
antibodies against SARS-CoV-2 administered systemically have shown clinical efficacy …
antibodies against SARS-CoV-2 administered systemically have shown clinical efficacy …
Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19
A Horga, DR Kuritzkes, JJ Kowalczyk… - Future …, 2023 - Taylor & Francis
Background: Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide
analogue inhibits SARS-CoV-2 replication in vitro. Materials & methods: Adults in hospital …
analogue inhibits SARS-CoV-2 replication in vitro. Materials & methods: Adults in hospital …
Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies
GC Barnard, M Zhou, A Shen, IH Yuk… - Biotechnology …, 2024 - Wiley Online Library
Monoclonal antibodies (mAbs) are effective therapeutic agents against many acute
infectious diseases including COVID‐19, Ebola, RSV, Clostridium difficile, and Anthrax …
infectious diseases including COVID‐19, Ebola, RSV, Clostridium difficile, and Anthrax …
Interface‐Guided Computational Protein Design Reveals Bebtelovimab‐Resistance Mutations in SARS‐CoV‐2 RBD: Correlation with Global Viral Genomes and …
S Maurya, S Kumar, AK Padhi - ChemistrySelect, 2023 - Wiley Online Library
The emergence of novel mutations in the SARS‐CoV‐2 spike protein challenges
monoclonal antibody (mAb) effectiveness. Comprehending resistance mutations and …
monoclonal antibody (mAb) effectiveness. Comprehending resistance mutations and …
Microfluidic-assisted single-cell RNA sequencing facilitates the development of neutralizing monoclonal antibodies against SARS-CoV-2
Z Wang, AS Huang, L Tang, J Wang, G Wang - Lab on a Chip, 2024 - pubs.rsc.org
As a class of antibodies that specifically bind to a virus and block its entry, neutralizing
monoclonal antibodies (neutralizing mAbs) have been recognized as a top choice for …
monoclonal antibodies (neutralizing mAbs) have been recognized as a top choice for …
Leveraging SARS-CoV-2 Main Protease (Mpro) for COVID-19 Mitigation with Selenium-Based Inhibitors
The implementation of innovative approaches is crucial in an ongoing endeavor to mitigate
the impact of COVID-19 pandemic. The present study examines the strategic application of …
the impact of COVID-19 pandemic. The present study examines the strategic application of …
Project NexGen: Developing the Next Generation of COVID-19 Vaccines and Therapeutics to Respond to the Present and Prepare for the Future
KA Hofmeyer, CL Ventura, KL Armstrong… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Coronavirus disease 2019 (COVID-19) epidemiology and product landscapes have
changed considerably since onset of the pandemic. Safe and effective vaccines and …
changed considerably since onset of the pandemic. Safe and effective vaccines and …